Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/123223
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Following positive results from the Phase III CHEST-1 study in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), the Phase IIIb CTEPH early access study (EAS) was designed to assess the safety and tolerability of riociguat in real-world clinical practice, as well as to provide patients with early access to riociguat before launch. Riociguat is approved for the treatment of inoperable and persistent/recurrent CTEPH. Methods: We performed an open-label, uncontrolled, single-arm, early access study in which 300 adult patients with inoperable or persistent/recurrent CTEPH received riociguat adjusted from 1 mg three times daily (tid) to a maximum of 2.5 mg tid. Patients switching from unsatisfactory prior pulmonary arterial hypertension (PAH)-targeted therapy (n = 84) underwent a washout period of at least 3 days before initiating riociguat. The primary aim was to assess the safety and tolerability of riociguat, with World Health Organization functional class and 6-min walking distance (6MWD) as exploratory efficacy endpoints. Results: In total, 262 patients (87%) completed study treatment and entered the safety follow-up (median treatment duration 47 weeks). Adverse events were reported in 273 patients (91%). The most frequently reported serious adverse events were syncope (6%), right ventricular failure (3%), and pneumonia (2%). There were five deaths, none of which was considered related to study medication. The safety and tolerability of riociguat was similar in patients switched from other PAH-targeted therapies and those who were treatment naïve. In patients with data available, mean ± standard deviation 6MWD had increased by 33 ± 42 m at Week 12 with no clinically relevant differences between the switched and treatment-naïve subgroups. Conclusions: Riociguat was well tolerated in patients with CTEPH who were treatment naïve, and in those who were switched from other PAH-targeted therapies. No new safety signals were observed.
Matèries (anglès)
Citació
Citació
MCLAUGHLIN, Vallerie v., JANSA, Pavel, NIELSEN-KUDSK, Jens e., HALANK, Michael, SIMONNEAU, Gérald, GRÜNIG, Ekkehard, ULRICH, Silvia, ROSENKRANZ, Stephan, GÓMEZ SÁNCHEZ, Miguel a., PULIDO, Tomás, PEPKE-ZABA, Joanna, BARBERÀ I MIR, Joan albert, HOEPER, Marius m, VACHIÉRY, Jean-luc, LANG, Irene, CARVALHO, Francine, MEIER, Christian, MUELLER, Katharina, NIKKHO, Sylvia, D'ARMINI, Andrea m.. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. _BMC Pulmonary Medicine_. vol. 17. Vol. 216. [consulta: 20 de gener de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/123223]